(UTI) Universal Technical - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US9139151040
Stock: Transportation, Skilled Trades, Healthcare, Training
Total Rating 41
Risk 55
Buy Signal -0.47
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 51.9% |
| Relative Tail Risk | -14.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.07 |
| Alpha | -24.97 |
| Character TTM | |
|---|---|
| Beta | 0.932 |
| Beta Downside | 1.024 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.36% |
| CAGR/Max DD | 1.31 |
Description: UTI Universal Technical January 16, 2026
Universal Technical Institute, Inc. (NYSE:UTI) delivers vocational education in transportation, skilled trades, and healthcare across the United States through two operating segments-UTI and Concorde-offering certificates, diplomas, and degrees, as well as manufacturer-specific advanced training and dealer-sponsored electives.
Key metrics to watch include enrollment growth (≈ +4% YoY in Q4 2023), average tuition per student (≈ $13,800), and the contribution margin of the Concorde segment, which has historically driven ~ 55% of total EBITDA. The business is sensitive to macro-economic factors such as automotive production volumes, dealer inventory cycles, and federal workforce development funding, all of which influence demand for technical up-skilling.
For a deeper, data-driven assessment of UTI’s valuation and risk profile, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 53.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -7.86 > 1.0 |
| NWC/Revenue: 3.60% < 20% (prev 3.76%; Δ -0.15% < -1%) |
| CFO/TA 0.09 > 3% & CFO 77.5m > Net Income 53.7m |
| Net Debt (365.6m) to EBITDA (126.9m): 2.88 < 3 |
| Current Ratio: 1.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (55.7m) vs 12m ago 0.61% < -2% |
| Gross Margin: 49.55% > 18% (prev 0.48%; Δ 4906 % > 0.5%) |
| Asset Turnover: 107.7% > 50% (prev 100.8%; Δ 6.95% > 0%) |
| Interest Coverage Ratio: 14.72 > 6 (EBITDA TTM 126.9m / Interest Expense TTM 5.08m) |
Altman Z'' 1.57
| A: 0.04 (Total Current Assets 248.7m - Total Current Liabilities 217.9m) / Total Assets 834.0m |
| B: 0.14 (Retained Earnings 114.4m / Total Assets 834.0m) |
| C: 0.09 (EBIT TTM 74.8m / Avg Total Assets 793.9m) |
| D: 0.23 (Book Value of Equity 115.2m / Total Liabilities 498.1m) |
| Altman-Z'' Score: 1.57 = BB |
Beneish M -1.87
| DSRI: 2.51 (Receivables 96.4m/34.2m, Revenue 855.0m/759.4m) |
| GMI: 0.98 (GM 49.55% / 48.35%) |
| AQI: 0.80 (AQ_t 0.11 / AQ_t-1 0.14) |
| SGI: 1.13 (Revenue 855.0m / 759.4m) |
| TATA: -0.03 (NI 53.7m - CFO 77.5m) / TA 834.0m) |
| Beneish M-Score: -1.87 (Cap -4..+1) = B |
What is the price of UTI shares?
As of February 07, 2026, the stock is trading at USD 25.52 with a total of 765,174 shares traded.
Over the past week, the price has changed by -8.30%, over one month by -7.06%, over three months by -9.54% and over the past year by -13.58%.
Over the past week, the price has changed by -8.30%, over one month by -7.06%, over three months by -9.54% and over the past year by -13.58%.
Is UTI a buy, sell or hold?
Universal Technical has received a consensus analysts rating of 4.83.
Therefore, it is recommended to buy UTI.
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the UTI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 37.3 | 46.3% |
| Analysts Target Price | 37.3 | 46.3% |
| ValueRay Target Price | 34.7 | 35.8% |
UTI Fundamental Data Overview February 07, 2026
P/E Trailing = 25.7813
P/E Forward = 36.63
P/S = 1.5926
P/B = 4.6714
P/EG = 2.4439
Revenue TTM = 855.0m USD
EBIT TTM = 74.8m USD
EBITDA TTM = 126.9m USD
Long Term Debt = 84.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 21.5m USD (from shortTermDebt, last quarter)
Debt = 459.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 365.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.66b USD (1.36b + Debt 459.1m - CCE 162.8m)
Interest Coverage Ratio = 14.72 (Ebit TTM 74.8m / Interest Expense TTM 5.08m)
EV/FCF = 100.0x (Enterprise Value 1.66b / FCF TTM 16.6m)
FCF Yield = 1.00% (FCF TTM 16.6m / Enterprise Value 1.66b)
FCF Margin = 1.94% (FCF TTM 16.6m / Revenue TTM 855.0m)
Net Margin = 6.28% (Net Income TTM 53.7m / Revenue TTM 855.0m)
Gross Margin = 49.55% ((Revenue TTM 855.0m - Cost of Revenue TTM 431.4m) / Revenue TTM)
Gross Margin QoQ = 49.72% (prev 49.80%)
Tobins Q-Ratio = 1.99 (Enterprise Value 1.66b / Total Assets 834.0m)
Interest Expense / Debt = 0.24% (Interest Expense 1.12m / Debt 459.1m)
Taxrate = 25.22% (21.3m / 84.3m)
NOPAT = 55.9m (EBIT 74.8m * (1 - 25.22%))
Current Ratio = 1.14 (Total Current Assets 248.7m / Total Current Liabilities 217.9m)
Debt / Equity = 1.37 (Debt 459.1m / totalStockholderEquity, last quarter 335.9m)
Debt / EBITDA = 2.88 (Net Debt 365.6m / EBITDA 126.9m)
Debt / FCF = 22.05 (Net Debt 365.6m / FCF TTM 16.6m)
Total Stockholder Equity = 316.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.76% (Net Income 53.7m / Total Assets 834.0m)
RoE = 16.98% (Net Income TTM 53.7m / Total Stockholder Equity 316.2m)
RoCE = 18.68% (EBIT 74.8m / Capital Employed (Equity 316.2m + L.T.Debt 84.2m))
RoIC = 14.17% (NOPAT 55.9m / Invested Capital 394.7m)
WACC = 7.04% (E(1.36b)/V(1.82b) * Re(9.35%) + D(459.1m)/V(1.82b) * Rd(0.24%) * (1-Tc(0.25)))
Discount Rate = 9.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.02%
[DCF Debug] Terminal Value 74.83% ; FCFF base≈39.6m ; Y1≈26.0m ; Y5≈11.9m
Fair Price DCF = N/A (negative equity: EV 280.7m - Net Debt 365.6m = -84.8m; debt exceeds intrinsic value)
EPS Correlation: 47.39 | EPS CAGR: 5.23% | SUE: -0.11 | # QB: 0
Revenue Correlation: 93.40 | Revenue CAGR: 22.85% | SUE: 1.74 | # QB: 12
EPS next Quarter (2026-03-31): EPS=0.02 | Chg30d=-0.054 | Revisions Net=-2 | Analysts=4
EPS current Year (2026-09-30): EPS=0.78 | Chg30d=+0.024 | Revisions Net=-1 | Growth EPS=-30.8% | Growth Revenue=+8.9%
EPS next Year (2027-09-30): EPS=0.89 | Chg30d=+0.004 | Revisions Net=-1 | Growth EPS=+13.6% | Growth Revenue=+8.8%
P/E Forward = 36.63
P/S = 1.5926
P/B = 4.6714
P/EG = 2.4439
Revenue TTM = 855.0m USD
EBIT TTM = 74.8m USD
EBITDA TTM = 126.9m USD
Long Term Debt = 84.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 21.5m USD (from shortTermDebt, last quarter)
Debt = 459.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 365.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.66b USD (1.36b + Debt 459.1m - CCE 162.8m)
Interest Coverage Ratio = 14.72 (Ebit TTM 74.8m / Interest Expense TTM 5.08m)
EV/FCF = 100.0x (Enterprise Value 1.66b / FCF TTM 16.6m)
FCF Yield = 1.00% (FCF TTM 16.6m / Enterprise Value 1.66b)
FCF Margin = 1.94% (FCF TTM 16.6m / Revenue TTM 855.0m)
Net Margin = 6.28% (Net Income TTM 53.7m / Revenue TTM 855.0m)
Gross Margin = 49.55% ((Revenue TTM 855.0m - Cost of Revenue TTM 431.4m) / Revenue TTM)
Gross Margin QoQ = 49.72% (prev 49.80%)
Tobins Q-Ratio = 1.99 (Enterprise Value 1.66b / Total Assets 834.0m)
Interest Expense / Debt = 0.24% (Interest Expense 1.12m / Debt 459.1m)
Taxrate = 25.22% (21.3m / 84.3m)
NOPAT = 55.9m (EBIT 74.8m * (1 - 25.22%))
Current Ratio = 1.14 (Total Current Assets 248.7m / Total Current Liabilities 217.9m)
Debt / Equity = 1.37 (Debt 459.1m / totalStockholderEquity, last quarter 335.9m)
Debt / EBITDA = 2.88 (Net Debt 365.6m / EBITDA 126.9m)
Debt / FCF = 22.05 (Net Debt 365.6m / FCF TTM 16.6m)
Total Stockholder Equity = 316.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.76% (Net Income 53.7m / Total Assets 834.0m)
RoE = 16.98% (Net Income TTM 53.7m / Total Stockholder Equity 316.2m)
RoCE = 18.68% (EBIT 74.8m / Capital Employed (Equity 316.2m + L.T.Debt 84.2m))
RoIC = 14.17% (NOPAT 55.9m / Invested Capital 394.7m)
WACC = 7.04% (E(1.36b)/V(1.82b) * Re(9.35%) + D(459.1m)/V(1.82b) * Rd(0.24%) * (1-Tc(0.25)))
Discount Rate = 9.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.02%
[DCF Debug] Terminal Value 74.83% ; FCFF base≈39.6m ; Y1≈26.0m ; Y5≈11.9m
Fair Price DCF = N/A (negative equity: EV 280.7m - Net Debt 365.6m = -84.8m; debt exceeds intrinsic value)
EPS Correlation: 47.39 | EPS CAGR: 5.23% | SUE: -0.11 | # QB: 0
Revenue Correlation: 93.40 | Revenue CAGR: 22.85% | SUE: 1.74 | # QB: 12
EPS next Quarter (2026-03-31): EPS=0.02 | Chg30d=-0.054 | Revisions Net=-2 | Analysts=4
EPS current Year (2026-09-30): EPS=0.78 | Chg30d=+0.024 | Revisions Net=-1 | Growth EPS=-30.8% | Growth Revenue=+8.9%
EPS next Year (2027-09-30): EPS=0.89 | Chg30d=+0.004 | Revisions Net=-1 | Growth EPS=+13.6% | Growth Revenue=+8.8%